Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Polymyositis and Dermatomyositis pipeline market research report includes an assessment of the disease epidemiology, leading marketed products, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for polymyositis and dermatomyositis (PM and DM). The report also analyzes the clinical and commercial landscapes of PM and DM, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Patients with PM and DM usually present with sub-acute or chronic onset of symmetric proximal muscle weakness, typical rash of DM (a distinguishing feature between DM and PM), often associated with high serum creatinine kinase levels.
What are the key MoA in the Polymyositis and Dermatomyositis pipeline market?
The key MoA in the Polymyositis and Dermatomyositis pipeline market are Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Cytotoxic to Cell. Enzyme Inhibitor has the highest number of pipeline products.
Polymyositis and Dermatomyositis pipeline market, by MoA
For more MoA insights, download a free report sample
What are the key RoA in the Polymyositis and Dermatomyositis pipeline market?
The key RoA in the Polymyositis and Dermatomyositis pipeline market are Oral, Injection, and Inhalational. Injection has the highest number of pipeline products.
Polymyositis and Dermatomyositis pipeline market, by RoA
For more RoA insights, download a free report sample
What are the key molecule type in the Polymyositis and Dermatomyositis pipeline market?
The key molecule type in the Polymyositis and Dermatomyositis pipeline market are Biologic and Small Molecule. Biologic has the highest number of pipeline products.
Polymyositis and Dermatomyositis pipeline market, by molecule type
For more molecule type insights, download a free report sample
What are the key sponsors in the Polymyositis and Dermatomyositis pipeline market?
Some of key sponsors in the Polymyositis and Dermatomyositis pipeline market are Pfizer, Ruijin Hospital, Novartis AG, CSL Ltd, Academic Medical Center, and Alexion Pharmaceuticals Inc. Pfizer has sponsored the highest number of clinical trials (eight) in PM/DM over the past 10 years, followed by Alexion, which has sponsored four trials.
Polymyositis and Dermatomyositis pipeline market, by sponsors
To know more about sponsors, download a free report sample
Market report overview
Key MoA | Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Protein and Peptide Inhibitor, Biological Factor Inhibitor, Cytotoxic to Cell |
Key RoA | Oral, Injection, and Inhalational |
Key molecule type | Biologic and Small Molecule |
Key sponsors | Pfizer, Ruijin Hospital, Novartis AG, CSL Ltd, Academic Medical Center, and Alexion Pharmaceuticals Inc |
Scope
GlobalData’s Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Polymyositis and Dermatomyositis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Polymyositis and Dermatomyositis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key MoA in the Polymyositis and Dermatomyositis pipeline market?
The key MoA in the Polymyositis and Dermatomyositis pipeline market are Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Protein and Peptide Inhibitor, Biological Factor Inhibitor, Cytotoxic to Cell.
-
What are the key RoA in the Polymyositis and Dermatomyositis pipeline market?
The key RoA in the Polymyositis and Dermatomyositis pipeline market are Oral, Injection, and Inhalational.
-
What are the key molecule type in the Polymyositis and Dermatomyositis pipeline market?
The key molecule type in the Polymyositis and Dermatomyositis pipeline market are Biologic and Small Molecule.
-
What are the key sponsors in the Polymyositis and Dermatomyositis pipeline market?
Some of key sponsors in the Polymyositis and Dermatomyositis pipeline market are Pfizer, Ruijin Hospital, Novartis AG, CSL Ltd, Academic Medical Center, and Alexion Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.